Revolution Medicines, Inc. RVMD
We are a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. 10-K, Item 1
- Headquarters
- Redwood City, CA
- CEO
- Mark A. Goldsmith
- Next results
- around Feb 24, 2027
RVMD among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 153 peers the company is above, not a score.
What changed
37 new risk paragraphs. 10-K filed Feb 25, 2026 against Feb 26, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
8 checks on the latest 10-K. Checks, not verdicts.
0facts worth reading about all 8 checks found nothing to note
-
Cash from operations −$897.7M vs net income −$1.1B (FY ending Dec 31, 2025)
-
Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
-
No statement of substantial doubt about going concern
5 more checks with nothing to note
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
37 paragraphs in Risk Factors that were not in the 10-K filed Feb 26, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
The Royalty Pharma Agreements place restrictions on our operating and financial flexibility. If we fail to comply with certain covenants in the Royalty Pharma Agreements, our financial condition and results of operations may be harmed. In June 2025, we entered into the Royalty Purchase Agreement with Royalty Pharma and the Loan…
-
Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
We are aware of several pharmaceutical companies developing products in the same class as our investigational products. See “Item 1. Business—Competition” for additional information regarding our competitors.
-
Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
The U.S. presidential administration has stated that it is pursuing a two-fold strategy to reduce drug costs in the U.S. While it is unclear whether and how these proposals will be implemented, they are likely to have a negative impact on the pharmaceutical industry and on our ability to receive adequate revenues for any product…
-
Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
We have received a Commissioner’s National Priority Voucher (CNPV) from FDA for daraxonrasib, but we may not realize any benefit from our participation in the FDA’s CNPV Pilot Program, and any changes to or termination of the CNPV Pilot Program could delay or adversely affect development and review of our product candidates. In June…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $35.4M | $11.6M | $0 | $0 |
| Net income | −$248.7M | −$436.4M | −$600.1M | −$1.1B |
| Operating cash flow | −$224.4M | −$350.6M | −$557.4M | −$897.7M |
| Free cash flow | −$235.2M | −$358.3M | −$567.7M | −$913.7M |
Revenue, FY2018 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$0 in FY2025−$1.1B in FY2025−$913.7M in FY2025
Recent filings
8 filings in the last 30 days · SEC EDGAR
-
Planned saleNov 12, 2026JACK LEE ANDERS (Officer) gave notice of a planned sale of 35,750 shares worth about $6.9M Form 144, approximate sale date Nov 11, 2026, under a 10b5-1 plan adopted Aug 12, 2026
-
Planned saleNov 4, 2026Elizabeth Anderson (a member of our board of directors) adopted a 10b5-1 trading plan reported in the 10-Q, up to 25,090 shares, runs to Jun 25, 2027
-
Planned saleNov 4, 2026Jack Anders (Chief Financial Officer) adopted a 10b5-1 trading plan reported in the 10-Q, up to 71,500 shares, runs to Aug 15, 2027
-
Planned saleNov 4, 2026Steve Kelsey, M.D (President, Research and Development) adopted a 10b5-1 trading plan reported in the 10-Q, up to 135,800 shares, runs to May 31, 2027
-
Planned saleNov 4, 2026Flavia Borellini (a member of our board of directors) adopted a 10b5-1 trading plan reported in the 10-Q, up to 14,624 shares, runs to Nov 17, 2027
About the company
Revolution Medicines, Inc., Redwood City, CA · from the 10-K filed Feb 25, 2026
We are a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. We possess sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Guided by our understanding of genetic drivers and adaptive resistance mechanisms in cancer, we deploy precision medicine approaches to inform innovative monotherapy and combination regimens.
- Headquarters
- Redwood City, CA
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 4, 2026
- Incorporated in
- DE
Email alerts
Sources
The 10-K filed Feb 25, 2026 (open at SEC), compared with the 10-K filed Feb 26, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RVMD/export.csv") into a cell.